The deal values Enaltec at a post-money valuation of ₹180-200 crore.
La Renon Healthcare, a pharmaceutical company has acquired 51% stake in EnaltecLabs. The deal values Enaltec at a post-money valuation of ₹180-200 crore.
Rajani Associates advised La Renon Healthcare and the team included:
- Transation Team - Poorvi Sanjanwala (Partner), Nishtha Mehta (Senior Associate),Kashmira Bakliwal (Senior Associate) and Rutvik Rajagopal (Associate)
- Diligence Team - Ankur Singhania (Partner), Kashmira Bakliwal and Rutvik Rajagopal.
Vertices Partners advised Enaltec Labs with a team led by Partners Amit Manubarwala and Vishal Mehta.
Managing Partner, Vinayak Burman provided strategic inputs.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.